Uncemented, 3-component total ankle replacements (TAR) have shown promising but somewhat varying results in medium- and long-term reports (Wood and Deakin [@CIT0029], Fevang et al. [@CIT0006], Skytta et al. [@CIT0027], Bonnin et al. [@CIT0003], Henricson et al. [@CIT0012], Mann et al. [@CIT0023], Tomlinson and Harrison [@CIT0028], Barg et al. [@CIT0001], Zaidi et al. [@CIT0030], Henricson and Carlsson [@CIT0009], Kerkhoff et al. [@CIT0017], Frigg et al. [@CIT0007], Palanca et al. [@CIT0024], Clough et al. [@CIT0004]). Some evidence points to better results with modern prosthetic designs (Barg et al. [@CIT0002], Koivu et al. [@CIT0018], Clough et al. [@CIT0004]). National registries give better insight into current real-world results, including more patients and different surgeons, than data from single surgeons or institutions. 5-year survival rates of between 0.78 and 0.89 have been reported by national registries from Finland, New Zealand, Norway, and Sweden (Fevang et al. [@CIT0006], Henricson et al. [@CIT0010], Hosman et al. [@CIT0014], Skytta et al. [@CIT0027], Henricson et al. [@CIT0012]). Results beyond 5 years are uncertain. Here we present medium and longer-term follow-up (up to 20 years) of TARs reported to the Swedish Ankle Registry (<http://www.swedankle.se>), and compare early and current designs.

Patients and methods {#s0002}
====================

Since 1993, Swedish hospitals performing TARs have reported information on date of index surgery and any revision surgery, including data on the patient and the procedure, to the Swedish Ankle Registry. The current procedure-based coverage and completeness are both estimated at close to 100%.

Until December 31, 2016, 1,230 primary TARs (all uncemented, 3-component designs) had been registered in 1,132 patients with mean annual numbers of 51 (6--87). The mean follow-up time was 7 years (0--24). 4 cases lost to follow-up were not included in the survival analyses. 546 of the remaining 1,226 cases we refer to as "early prosthetic designs" (STAR, BP, and AES) as these designs have not been implanted in Sweden since 2008; the other 680 we refer to as "current prosthetic designs" (Hintegra, Mobility, CCI, Rebalance, and TM Ankle) ([Table 1](#t0001){ref-type="table"}). Revision was defined as removal or exchange of 1 or more of the prosthetic components with the exception of incidental exchange (exchange of the polyethylene insert during a secondary procedure undertaken because of a different indication) of the polyethylene insert (Henricson et al. [@CIT0011]). We chose to analyze the number of prostheses rather than the number of patients (including 96 bilateral cases), in line with our previous study (Henricson et al. [@CIT0012]) as this approach has been found to have a negligible effect on the survival estimates (Ranstam and Robertsson [@CIT0025]).

###### 

Distribution of TARs implanted in Sweden during 1993--2016 by year of implantation and prosthetic design

          Early prosthetic designs   Current prosthetic designs                                     
  ------- -------------------------- ---------------------------- ----- ---- ----- ----- ----- ---- -------
  1993    6                                                                                         6
  1994    13                                                                                        13
  1995    11                                                                                        11
  1996    8                                                                                         8
  1997    24                                                                                        24
  1998    34                                                                                        34
  1999    25                         1                                                              25
  2000    45                                                                                        46
  2001    48                         21                           3     10                          48
  2002    39                         23                           17    14                          73
  2003    25                         29                           16    4                           79
  2004    18                         13                           23    2    9                      67
  2005    18                         11                           21    6    21                     65
  2006    8                          7                            18         20                     67
  2007    1                          4                            17         32    16               46
  2008                                                                       31    42               69
  2009                                                                       41    22               73
  2010                                                                       44    22    21         63
  2011                                                                       23    31    27         87
  2012                                                                       32    12    34         81
  2013                                                                       15    4     37    5    78
  2014                                                                       1     2     36    11   61
  2015                                                                  3                23    21   53
  2016                                                                  9                           53
  Total   323                        109                          115   48   269   151   178   37   1,230

Scandinavian Total Ankle Replacement (Waldemar LINK GmBH, Hamburg, Germany)

Buechel--Pappas (Wright Cremascoli, Toulon, France)

Ankle Evolutive System (Biomet, Valence, France)

Hintegra (Newdeal SA, Lyon, France)

Mobility (DePuy International, Leeds, UK)

CCI--Ceramic Coated Implant (Wright Medical Technology, Arlington)

Rebalance (Biomet, Bridgend, UK)

Trabecular Metal Total Ankle (Zimmer inc, Warsaw, Indiana, USA)

Since 1993, TAR has been performed in 25 hospitals in Sweden by 43 surgeons. In the total cohort, 60% were women and the mean age at primary TAR was 60 years (18--88). The most common primary diagnoses leading to surgery were posttraumatic arthritis in one-third of patients and rheumatoid arthritis in one-third ([Table 2](#t0002){ref-type="table"}).

###### 

Data on distribution of diagnoses, sex and age per prosthetic design group

  Design group Diagnosis                   n (%)      women (%)   Age mean (SD) \[range\]
  ---------------------------------------- ---------- ----------- -------------------------
  All prosthetic designs                                          
   Posttraumatic arthritis                 443 (36)   53          60 (12) \[25--86\]
   Rheumatoid arthritis                    401 (32)   81          56 (14) \[18--85\]
   Osteoarthritis                          291 (24)   46          64 (11) \[30--88\]
   Other[^a^](#TF9){ref-type="table-fn"}   95 (8)     40          59 (12) \[28--76\]
   All diagnoses                           1,230      60          60 (13) \[18--88\]
   Current prosthetic designs                                     
   Posttraumatic arthritis                 268 (39)   52          62 (12) \[30--85\]
   Rheumatoid arthritis                    182 (27)   87          57 (14) \[18--83\]
   Osteoarthritis                          155 (23)   45          67 (10) \[37--88\]
   Other[^a^](#TF9){ref-type="table-fn"}   78 (11)    37          60 (11) \[34--76\]
   All diagnoses                           683        58          62 (12) \[18--88\]
  Early prosthetic designs                                        
   Posttraumatic arthritis                 175 (32)   54          56 (12) \[25--86\]
   Rheumatoid arthritis                    219 (40)   77          56 (14) \[21--85\]
   Osteoarthritis                          136 (25)   48          61 (10) \[30--84\]
   Other[^a^](#TF9){ref-type="table-fn"}   17 (3)     53          53 (15) \[28--74\]
   All diagnoses                           547        62          57 (13) \[21--86\]

Including hemophilia, hemochromatosis and psoriatic arthritis

Statistics {#s0003}
----------

To visualize differences in prosthetic survival rate, we used Kaplan--Meier estimator. Differences between current and early prosthetic designs were examined by log rank test.

Data are reported as numbers and proportions (%), mean (SD), or median (range). We considered a probability of less than 5% as statistically significant and used 95% confidence intervals (CI) within parentheses to describe uncertainty.

Even though our study may not be considered sample based we have chosen to present measure of uncertainty in order to facilitate generalization to probable future outcomes in Sweden and to other similar populations. We used SPSS version 23 (IBM Corp, Armonk, NY, USA).
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------------------------------------------------------------------
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Results {#s0005}
=======

Of the 1,230 prostheses implanted since 1993, 22% had been revised by December 31, 2016. The most common reason for revision was loosening of the tibial and/or the talar component, responsible for about half of the revisions in both the early design group and current design group. PE (polyethylene) insert failure (13%) was the second most common reason for revision in the early design group, whereas this was only reported once in the current design group ([Table 3](#t0003){ref-type="table"}).

###### 

Information on reasons for revision for early prosthetic designs

  Reasons for revision            STAR n = 323   BP n = 109   AES n = 115   Total (%)n = 547
  ------------------------------- -------------- ------------ ------------- ------------------
  Talus and/or tibia                                                         
   loosening                      65             7            16            88 (45)
  Technical error                 17 **^a^**     2            19 (10)        
  Instability                     1              3            3             7 (4)
  Infection                       16             1            4             21 (11)
  Intractable pain                10             1            1             12 (6)
  PE failure                      22             2            2             26 (13)
  Painful varus                   2              2            2             6 (3)
  Painful valgus                                 1            4             5 (3)
  Fracture/dislocation            3              3            2             8 (4)
  Other                                                       5             5 (3)
  Total number of revisions (%)   136 (42)       22 (20)      39 (34)       197 (36)

We found an overall TAR survival at 5 years of 0.85 (95% CI 0.83--0.87), at 10 years 0.74 (CI 0.70--0.77), at 15 years 0.63 (CI 0.58--0.67) and at 20 years 0.58 (CI 0.52--0.65) ([Figure 1](#F0001){ref-type="fig"}).

![Estimated cumulative prosthetic survival for all 1,226 TARs. Number of patients still at risk of experiencing the primary endpoint and prosthetic survival with 95% CI per 5-year period are indicated in the life table](IORT_A_1709312_F0001_C){#F0001}

For early and current designs 10-year TAR survival was 0.69 (CI 0.64--0.73) and 0.84 (CI 0.79--0.88) respectively ([Figure 2](#F0002){ref-type="fig"}). Log rank test revealed a statistically significant difference in TAR survival between early and current designs in favor of current designs (p \< 0.001) ([Figure 2](#F0002){ref-type="fig"}).

![Estimated cumulative prosthetic survival for early and current designs. Number of patients still at risk of experiencing the primary endpoint and prosthetic survival with 95% CI per 5-year period are indicated in the life table](IORT_A_1709312_F0002_C){#F0002}

Analyses by specific prosthetic design revealed a 5-year TAR survival rate of 0.89 (CI 0.82--0.97) for the currently most implanted design in Sweden, Rebalance. At the time of writing, no revision of TM Ankle design had been reported to the registry ([Figures 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"}).

![Estimated cumulative prosthetic survival for early designs. Number of patients still at risk of experiencing the primary endpoint and prosthetic survival with 95% CI per 5-year period are indicated in the life table.](IORT_A_1709312_F0003_C){#F0003}

![Estimated cumulative prosthetic survival for current designs. Number of patients still at risk of experiencing the primary endpoint and prosthetic survival with 95% CI per 5-year period are indicated in the life table.](IORT_A_1709312_F0004_C){#F0004}

We found similar TAR survival rates (ranging from 0.57 to 0.69 at 15 years) for different diagnoses (Figure 5, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1709312)).

Discussion {#s0006}
==========

Using the Swedish Ankle Registry, we have demonstrated that survival of current TAR prostheses is higher than for earlier designs. In previous reports from our national registry the 5-year TAR survival rates were 0.78 for procedures made from 1993 to 2005 (Henricson et al. [@CIT0010]) and 0.81 for 1993 to 2010 (Henricson et al. [@CIT0012]) respectively. In the current report we found the corresponding survival to be 0.85, indicating an improvement over time. This notion is further supported by 10-year TAR survival of 0.74 in the current study ([Table 4](#t0004){ref-type="table"}, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1709312)) and 0.69 in the previous (Henricson et al. [@CIT0012]) (procedures undertaken from 1993 to 2010). In Sweden today, fewer units and surgeons perform TAR compared with earlier, resulting in larger volumes per surgeon. This and the presumed growing experience of these surgeons associated with time, may have contributed to the improving results.

###### 

Information on reasons for revision for current prosthetic designs

  Reasons for revision            Hintegra n = 48   Mobility n = 269   CCI n = 151   Rebalance n = 178   TM ankle n = 37   Total (%)n = 683
  ------------------------------- ----------------- ------------------ ------------- ------------------- ----------------- ------------------
  Talus and/or tibia loosening    4                 8                  18            5                                     35 (49)
  Technical error                 2                                    1             1                                     4 (6)
  Instability                     1                 4                  1             1                                     7 (10)
  Infection                       1                 1                  1                                                   3 (4)
  Intractable pain                                  6                  4             1                                     11 (15)
  PE failure                                        1                                                                      2 (3)
  Painful varus                                     1                  2             1                                     4 (6)
  Painful valgus                  1                 1                                                                      2 (3)
  Fracture/Lux                                      1                                                                      1 (1)
  Other                                             2                  1                                                   2 (3)
  Total number of revisions (%)   9 (19)            25 (9)             28 (19)       9 (5)               0 (0)             71 (10)

The inferior results of the STAR prosthesis is documented in previous reports from the Swedish Ankle Registry (Henricson and Carlsson [@CIT0009]). The high frequency of "technical errors" may partly be explained by suboptimal instrumentation, limited experience of surgeons, and technical demands (Henricson et al. [@CIT0012]).

Reports from other national registries, published between 2007 and 2017, have presented 5-year survival rates between 0.78 and 0.89 and 10-year rates between 0.69 and 0.83, thus comparable to our findings, although the definition of revision is not always identical to our report ([Table 4](#t0004){ref-type="table"}, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1709312)). In comparison with nationwide registries, results from single-center specialized units are often better (Labek et al. [@CIT0021]), but have seldom been reproduced in countries where national registry data are available. Several such studies report 15-year survival rates between 0.64 and 0.76 ([Table 4](#t0004){ref-type="table"}). This may be due to larger volumes of TARs per surgeon and also case mix, and supports the notion that TAR surgery takes a long time to master (Henricson et al. [@CIT0013], Barg et al. [@CIT0002]).

Follow-up of 15 years or more has to our knowledge not previously been published by any other national registry. We found TAR survival rates at 15 years of 0.63 and at 20 years of 0.58. It is perhaps encouraging that long-term survival beyond 15 years is good with little change in survival between then and 20 years, although this inference is drawn from few patients. If we compare our 15-year TAR survival rates with 0.80 after knee arthroplasty and 0.88 after hip arthroplasty (Koskinen et al. [@CIT0020], Makela et al. [@CIT0022]), the results are still, as previously noted, clearly inferior (Labek et al. [@CIT0021]).

The general trend seems to be an increase in the use of TAR for treatment of ankle arthritis (Zaidi et al. [@CIT0030], Rybalko et al. [@CIT0026]), although we did not find this to be true in Sweden. During 2016, 53 total ankle replacements were performed in Sweden (10 million inhabitants, 9 million inhabitants ≥ 15 years) indicating 0.6 replacements per 10^5^ inhabitants over the age of 15, a decrease compared with 1/10^5^ during 2011 when the incidence had plateaued (Henricson et al. [@CIT0012]). The low numbers in Sweden may partly be explained by logistical factors and staffing shortage in operating units and local procurement of prosthetic designs during recent years. A tendency of fewer patients with RA requiring TAR has also been noted during recent years, perhaps representing benefits of better non-surgical treatment.

For the early and current prosthetic design groups, 10-year TAR survival rate was 0.69 (CI 0.64--0.73) and 0.84 (CI 0.79--0.88) respectively ([Figure 2](#F0002){ref-type="fig"}). This may in part be referred to better prosthetic designs including instrumentation, but also to increasing surgeon experience, more careful patient selection, and improved healthcare.

Concerning separate prosthetic designs, we found that the currently most implanted models in Sweden (TM Ankle and Rebalance) show promising short-term results. Harris et al. ([@CIT0008]) studied 220 Rebalance prostheses, and similarly found encouraging early results. Some of the early models, such as AES, were withdrawn due to higher than expected complication rates (Di Iorio et al. [@CIT0005], Koivu et al. [@CIT0019]). Robust long-term follow-up results are important.

The most common reason for revision was loosening of the tibial and/or the talar component, accounting for about half of the revisions in both the early design group and current design group. Loosening has also been found to be the most common complication in several other studies from national registries as well as specialized/high-volume units (Barg et al. [@CIT0002]). Polyethylene failure was the second most common complication in the early design group, whereas this complication was reported only once in the current design group. This may indicate improvement in implant design or manufacturing but may also partly be the result of longer follow-up of earlier designs. Further in-detail examination is necessary, preferably in a collaboration between several national registries.

In Sweden, available options of prosthetic designs are dictated by local procurement arrangements, which are based on local review of scientific reports and reports from the industry. This underlines the importance of future independent real-world studies from national registries.

The strength of national registry data is the real-world representation, i.e., data from several different surgeons and units, thus giving a picture of actual results in contrast to reports from single units or surgeons. Furthermore, this study has to our knowledge the hitherto largest cohort and follow-up time from a national ankle registry. Age, sex, and primary diagnosis seem overall to be similar to what has been reported in the literature.

The generalizability of our results may be limited. Data are derived from the specific setting of the Swedish Ankle Registry and results must be interpreted with care. However, results may still be applicable to similar populations ([Table 2](#t0002){ref-type="table"}).

Another limitation of registry data is the uncertainty as to whether reporting is accurate and complete. We are confident that the reporting of primary TARs and revisions to the Swedish national ankle registry are accurate as the data are continuously compared with official data from the Swedish National Patient Registry by personal identity number and because the community of surgeons performing TARs is small. Furthermore, prosthetic failure was estimated from the date of the revision surgery, not from the date when failure was established. In addition, only revisions are reported, not failed implants that have not been revised. Given the observational study design, we cannot draw any causal inferences.

In conclusion, use of current prosthetic designs was associated with better TAR survival. This may in part reflect better prosthetic designs and instrumentation, but also increasing surgeon experience and better patient selection, as well as improved healthcare. However, TAR has a long way to go to approach survival rates for hip and knee arthroplasty.
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Figure 5 and Table 4 are available as supplementary data in the online version of this article, http://dx.doi.org/10.1080/17453674.2019.1709312
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